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Introduction
Breast cancer is one of the most important
malignant tumours in the world. It is the second most
frequent cause of death in west.1 In recent years the
prevalence of breast cancer in Asia, including Iran, has
increased and it is the third major cause of death in Iran.2
Breast cancer is associated with a number of environmental
factors and genetic disorders.3
Genes related to breast cancer are divided into two
groups: (a) Tumour suppressor genes which hamper
tumour growth e.g. p53 gene whose product is a
phosphoprotein composed of 393 amino acids with a role
in various cell functions such as apoptosis, transcription
and senescence.4 (b) Genes which lead to the progress of
the tumour such as ki67 gene that codes a proliferating
cell nuclear antigen (PCNA) which is a non histonic
protein with a life time of 60 to 90 minutes.5 The Ki67
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Abstract
Objective: To investigate and compare the prognostic value of P53 and Ki67 markers in patients with breast
cancer in Sabzevar, north east of Iran. 
Methods: A descriptive analytical study was conducted on 80 patients with breast cancer who were admitted to
the hospitals in Sabzevar in 2006 and they were followed up to 2010. The expression of ki67 and stability of p53
genes were determined by immunohistochemistry. To assess the disease prognosis, patients were followed up
to 48 months. Data were analyzed using SPSS software version 11.5. Chi-square, Fisher's exact test, Kaplan-
Miere and Log Rank tests were used for statistical purposes.
Results: Eighty cancerous tissue samples were examined. The Ki67 marker was present in 37 (46.3%) cases and
the P53 protein stability in 39 (48.8%) cases were observed. There was a significant relationship between ki67
gene expression and tumour stage (p = 0.001) or tumour type (P = 0.02). There was also a significant relationship
between the survival rate and the tumor stage (P = 0.008). The Ki67 marker had significant relationship with the
survival rate (P = 0.031), but over expression of P53 protein did not show such significance (P = 0.385). 
Conclusion: The results showed that the Ki67 marker was more important than P53 protein in prognosis of the
breast cancer patients. 
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marker can be detected by immunohistochemistry
method in dividing cells because PCNA is active
throughout all cell circle stages including Gap1, S, Gap2
and mitosis.6
Though some researchers have suggested that
Ki67 marker and the PCNA measurement would be
valuable markers in prognosis of breast cancer,7,8 there is
no consensus in this regard as some other authors did not
consider this marker as a predictive factor.9 Therefore,
the diagnosis, management and treatment of patients with
breast cancer issue has remained a controversial dilemma
and needs further investigations.10 Taken together, the
value of P53 and Ki67 markers have not been yet
established as a constant factor in determination of the
prognosis of breast cancer. There is also not sufficient
information regarding the survival rate of these patients
and its relationship with these biomarkers in Sabzevar,
north east of Iran. The present study was therefore,
conducted to investigate the expression and prognostic
value of these markers and their relationship with
survival rate in breast cancer patients in this part of Iran.
Patients and Methods
A descriptive analytical study was conducted on
80 patients with breast cancer who were admitted to the
hospitals in Sabzevar in 2006 and followed up to 2010.
All positive breast cancer specimens in this year were
selected for the study. The diagnosis was made by two
expert pathologists. This study was approved by the
committee of ethics guidelines in Sabzevar University of
Medical Sciences. Samples were collected before the
patients received any radiotherapy and/or chemotherapy.
Samples were fixed in 10% formalin immediately after
the surgery, and tissue passage was done after 24 hours.
Four-micron thick series sections were stained then by
Haematoxylin and Eosin (H&E) method. After diagnosis
and confirmation of malignancy by two pathologists who
blindly examined the specimens, immunohistochemical
examination was conducted on the samples. Normal
breast tissues of patients were prepared as above and
used as controls. 
Histological grading was performed based on the
three following parameters, mitotic activity, nuclear
pleomorphism and the extent of tubule formation by
microscopy of the slides. Grades were therefore proposed
in three groups: I, II and III.11 Tumour stages in breast
cancer were designated numbers as: in situ carcinoma,
(0), and four possible stages including stage I, II, III, and
IV.12
For antigen retrieval, the sections were placed in a
coupling containing buffer citrate solutions (PH=6,
molarity 0.01), and were kept in a microwave oven at
95°C for 20 minutes. After tissue peroxidase inhibition,
the sections were then washed by phosphate buffer saline
(PBS) 3 times. The primary monoclonal antibodies
including the P53 (DAKO company) and the Ki67 mouse
monoclonal antibodies (Novocostra, UK) were added at
room temperature for at a 1/50 dilution for one hour.
After being washed thrice with PBS the slides were
incubated with biotinylated secondary antibody for 15
minutes. The slides were then washed three times with
PBS and thereafter sections were stained with 3, 3'-
Diamino benzidine (DAB) substrate solution. The
streptavidin linked to Horse Radish Peroxidase (HRP) is
capable of oxidizing DAB. Cells associated with the P53
and ki67 genes expression would make up a brown
colour non-soluble precipitation. 
The stained tissue backgrounds with haematoxylin
were dehydrated and mounted. These slides were studied
by a light microscopy. When the stained cells were less
than 10% of total they were regarded as negative,
between 10% to 25% the cells considered 1 positive (+);
between 26% to 50% they were considered 2 positive (+
+) and when over 50% of the cells were stained they were
considered as 3 positive (+ + +).13
All patients were followed up to 4 years. We
contacted the family of all patients and checked their
current status. 
Statistical Analysis:
Data analyzing was performed using SPSS
software 11.5 and chi-square and Fisher's exact tests
were performed when required. By using Kaplan-Meier
method and Log Rank test, the relationship between the
survival rates of those patients with biomarkers and
tumour stage were also evaluated. Significant differences
were considered when p value was less than 0.05 in all
experiments.
Results
A total of eighty cases with breast cancer were
involved of which 79 cases were females and one case
was a male (35-years age). Their age ranged between 20
and 86 years with a mean of 48.78±14.82. In 17 (21.3%)
cases the carcinoma was in situ or at 0 stage, in 30
(37.5%) cases at the first stage and in 25 (31.3%) cases at
the second stage, in 6 (7.5%) cases at the third stage and
in 2 (2.5%) cases at the fourth stage. One of them had
metastasis into the lung and another one into the chest.
According to the grades, out of 80 cases, 59 were at the
grade 1, 18 cases at grade 2, and the rest 3 cases were at
grade of 3.
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P53 Protein Stability and The Ki67 Marker:
In the present study the P53 protein stability was
observed in 39 (48.8%) cases. The P53 protein stability
was designated (+) in 21 cases, (++) in 10 cases and
(+++) in 8 cases (Figure-1 A and B). The stained cells
were considered as cancerous because of the presence of
the P53 protein stability. Such stability was not observed
in 41 (51.3%) cases, and the cancerous cells were not
stained brown by immunohistochemical methods
(Figure-1 C). No significant relationship was observed
between tumour stage and P53 protein stability in the
cancerous cells in the breast tissue (p = 0.16).
The Ki67 proliferative marker was observed in 37
cases out of 80 cases with breast cancer. Their staining
slides were (+) in 15 cases, (++) in 14 cases, and (+++)
in 8 cases (Figure-1 D, E and F). The ki67 gene
expression was negative in 43 cases. 
The Table shows that there is a statistically
significant (p = 0.001) relationship between the tumour
stage and the Ki67 proliferative marker. However, there
was no significant relationship (p = 0.08) between the
tumour grade and the ki67 gene expression. Fisher's
exact test showed a significant relationship (p = 0.026)
between the tumour type and the ki67 gene expression.
Since the cells had expected count less than 5 in table 1,
the chi-square test could not be applied, so according to
statistical consultation, stage 2 and stage 3 frequencies
were combined in table 1 to obtain a considerable
reliability. 
At the end of the four years follow up period 33
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Figure-1: Four-micron cross section of cancerous breast tissue, showing the A (+++),
B (++) P53 protein stability, C (P53 protein instability), D (+++), E (++), F (+) Ki67
gene expression. Cancerous cells have been stained brown by immunohistochemistry.
(magnification 400x). 
Figure-2: Kaplan-Meier survival curves for P53 protein stability (A) and Ki67 marker
(B) in breast cancer patients.
patients had died. One patient the lone male died within
the first year after diagnosis while his Ki67 marker and
P53 protein tests were negative. During four years follow
up 32 women died. In 20 (62.5%) of those patients the
Ki67 marker was positive and in 12 (37.5%) it was
negative. The results showed that the over expression of
P53 protein had no significant (P = 0.385) relationship
with survival rate, but the presence of the Ki67 marker
had significant (P = 0.031) relationship. There was also a
significant relationship (P = 0.008) between the survival
rate and the tumour stage (Figure 2). The prognosis in the
patients with more advanced stages 3 and 4 of breast
cancer had significantly worsened than that in those with
stages 0, 1 and 2 (Log Rank test P value = 0.008). There
was no significant relationship (P = 0.2) between the
tumour grade and the survival rate in the patients.
Discussion
Of the 80 patients with breast cancer, the Ki67
marker was positive in 37 (46.3%) cases, whereas the
P53 protein stability was observed in 39 (48.87%) cases.
There was a significant relationship between the tumour
stage and the ki67 gene expression but no significant
relationship was observed between the tumour stage and
P53 protein stability. Our findings were consistent with
Tan et al who found that the P53 protein stability was
present in 59 (49%) cases out of 102 breast cancer cases
in Singapore.14 In a study in Japan, Yamashita et al
investigated 73 breast cancer cases and observed p53
protein stability in 16 (21.9%) cases which were
significantly resistant against hormone therapy compared
with controls.15 In a study in France in which sera of 158
breast cancer cases at stages 3 and 4 were examined, the
P53 specific antibody was detected in 30 (19%) cases.16
Although those results are different from our findings,
the difference is probably due to the method of the study
as we examined and detected the P53 monoclonal tissue
specific antibody in the breast cancer cases. We have,
therefore, proposed that factors stated above are involved
in the various patterns in the expressions of p53 gene and
its mutation. In this respect, it is shown that the higher
expressions of this gene are created in the higher grades
and in invasive tumours.17
Pinder et al in a study in the UK found a
significant relationship between the tissue grade and the
Ki67 proliferative marker.18 Similarly, we found, a
significant relationship between the presence of Ki67
marker and P53 protein stability. Our results also
demonstrated, as Kaplan-Meier test confirmed, that the
survival rate in those who were positive for Ki67 marker
was less compared to those who were negative. We also
found that the relationship between tissue grade and the
Ki67 factor was not significant which is similar to the
results of the Tan et al who reported that increasing the
ki67 gene expression was related to the higher
histological grades and mitosis.19 However, Mylonas et
al in Germany found a significant relationship between
the Ki67 factor and ductal carcinoma. However that
study did not show such a relationship between the
tumour type and the P53 protein stability.20 Ringberg et
al in Sweden examined the presence of the Ki67 marker
in 170 breast cancer cases. They observed that the Ki67
marker was present in 72 (42%) cases, but they did not
find any significant relationship between the cancer and
some biological factor such as the age (mean age was 58
years).21 The result was similar to our findings in terms
of the ki67 gene expression rate but it was different in
terms of the age as the mean age in our study was nearly
10 years less. This indicates that in Sabzevar, breast
cancer may initiate in earlier ages compared with other
areas such as Sweden. Therefore, this issue merits more
investigations in terms of other possible influencing
factors.
Earlier reports have shown that the prevalence of
breast cancer is less than 1% in men.22 As expected, we
detected the breast cancer in only one male who died in
the first year after the diagnosis. However, in his
collected sample both P53 protein and the Ki67 marker
were negative. This case was at the stage 3 at the time of
diagnosis. As there is not enough information about
breast cancer among males, the cancer may be diagnosed
at an advanced stage and with unfavourable prognosis.
We also found that 32 women died within four years of
our follow up. According to several studies, classical and
novel prognostic factors are important in the prediction
of the survival rate.23
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Table: The frequency of the ki67 gene expression in the different tumor stages in the cells of the breast cancer tissue (p < 0.001).
Ki67 Stage Positive Negative Total
N Percent N Percent N Percent
Zero 1 1.3 16 20 17 21.3
One 12 15 18 22.5 30 37.5
Two and three 22 27.5 9 11.3 31 38.8
Four 2 2.5 0 0 2 2.5
Total 37 46.3 43 53.8 80 100
Conclusions
Results of the study suggested that the Ki67
marker is likely an important factor in the prognosis of
breast cancer compared with the P53 protein in north
eastern Iran. To the best of our knowledge it is the first
report about the prognosis of the breast cancer in
Sabzevar which is a thickly populated area in Iran.
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